linjc16/ctgov huggingface dataset:
Use of the Quantra QPlus Sytem in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Single center retrospective study evaluating the impact of using the Quantra QPlus System to guide transfusion decisions on postoperative outcomes in patients undergoing cardiac surgery.

Detailed Description
-----------------
Yavapai Regional Medical Center (YRMC) implemented the Quantra QPlus System to aid in their efforts to effectively reduce the transfusion rate of allogenic blood products and improve outcomes in patients undergoing cardiac surgery. Use of the Quantra to guide decisions related to the use of blood products in cardiac surgery patients began in 2019. In this retrospective study, YRMC evaluated the impact of using the Quantra QPlus System to guide transfusion decisions on postoperative outcomes in patients undergoing cardiac surgery.

Official Title
-----------------
Utilization of the Quantra QPlus System to Guide the Management of Blood Product Transfusions in Cardiac Surgery Patients: Effects on Clinical and Economic Outcomes

Conditions
-----------------
Cardiovascular Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: Quantra QPlus System


Participation Criteria
=================
Eligibility Criteria
-----------------
Pre-Quantra Group: All consecutive patients undergoing cardiac surgical procedures during the period from January 2019 to September 2019 (n=64) Post-Quantra Group: All consecutive patients undergoing cardiac surgical procedures during the period from May 2020 to April 2021 (n=64)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pre-Quantra<br>Patients undergoing cardiac surgery prior to the introduction of the Quantra. | |
| Post-Quantra<br>Patients undergoing cardiac surgery after the introduction of the Quantra. | Diagnostic Test: Quantra QPlus System<br>* Coagulation monitoring system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood product utilization | Units of blood products administered to patient | Intraoperative - during surgery | 
| Blood product utilization | Units of blood products administered to patient | Postoperative - after surgery throughout the rest of the hospital stay, assessed up to 30 days | 
| Cost of blood products | Total cost of blood products administered to patient | Throughout the entire hospital stay, assessed up to 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiac surgery, Quantra, Viscoelastic testing, Coagulation, QPlus
Fetuin A in Hashimoto Thyroiditis

Study Overview
=================
Brief Summary
-----------------
Fetuin-A levels are reported to be low as a negative acute phase reactant in systemical inflammatory situations. Hashimoto thyroiditis is characterized with inflammation. In this study, we hypothesised that the serum fetuin A levels could be found to be low due to inflammation in patients with Hashimoto thyroiditis

Detailed Description
-----------------
Patients ≥ 20 years of age being followed up at the outpatient clinics of the Internal Medicine Department in Medeniyet University Goztepe Training and Research Hospital and fulfilling the eligibility criteria will be included in the study. Approval of the local ethics committee and informed consent of the participants will be received for the study. The study is conducted in accordance with the Declaration of Helsinki. Demographic characteristics, concomitant diseases, smoking and alcohol drinking habits, concomitant medication usage, anthropometric and biochemistry data of the eligible patients will be recorded. Patient group will consist of patients with newly diagnosed Hashimoto thyroiditis and the control group will consist of healthy volunteers. Groups will be compared according to their demographic, an¬thropometric and biochemistry data and serum fetuin-A levels. In order to detect the relationship between the serum fetuin-A levels and clinical features, correlation analyses will be done.

Official Title
-----------------
Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis

Conditions
-----------------
Hashimoto Thyroiditis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients newly diagnosed with Hashimoto thyroiditis Exclusion Criteria: Acute infection Acute or chronic inflammatory disease Anti-inflammatory treatment (non-steroidal anti-inflammatory, corticosteroids etc.) Hypoxic situations (chronic obstructive pulmonary disease etc.) Severe heart, kidney and liver disease Pregnancy Endocrine disorders Malignancy Usage of drug that affects thyroid hormone levels

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group of Hashimoto thyroiditis patients<br> | |
| Healty control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of serum fetuin A levels between patients with Hashimoto thyroiditis and healthy subjects |  | 1 day (The blood samples were obtained on the same day participants arrived to outpatient clinics.) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute phase reactant, fetuin A, Hashimoto thyroiditis
Demographic , Clinicopathological Characteristics and Survival of Breast Cancer

Study Overview
=================
Brief Summary
-----------------
The investigators will retrospectively study the demographic , clinicopathological characteristics and survival of breast cancer patients admitted to Assiut University hospital from the year 2015 to 2019

Detailed Description
-----------------
Breast cancer is one of the most common malignancies in females, which is the second leading cause of cancer death throughout the world after lung cancer . The incidence of breast cancer has been increasing over the past decades , especially in young women (≤ 35 years old). There is approximately 182,000 women with breast neoplasm annually in the United States, accounting for about 26% of all incident cancers among women. In Asia, the morbidity rate is as high as 9.5%-12% . Even worse in China, the average onset age of breast cancer might be 8-10 years younger than that in Western countries which account for upto 4% in total breast cancer patients . In Egypt, breast cancer is the commonest type of female malignancy represented about 38.8% among common cancer sites in females.Although The unclear etiology of the majority of breast cancer, but there are numerous risk factors for the disease. Screening and early detection when combined with adequate, efficient treatment is considered the hope for a reduction of mortality in breast cancer as postulated by World Health organization (WHO).

Official Title
-----------------
Demographic, Clinicopathological Characteristics and Survival of Breast Cancer Patients in Assiut University Hospital (2015-2019).

Conditions
-----------------
Breast Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All histologically confirmed and documented patients with invasive ductal or lobular carcinoma of the breast attending at Assiut University hospital from year 2015 to 2019. Exclusion Criteria: • Patients who previously received treatment outside Assiut University hospital. A serious un controlled concomitant disease that would contraindicate with use of systemic treatment. .

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The survival rate of breast cancer in assiut university hospital | The number of patients survived after surgery or chemotherapy | One year |
Evaluation of the Impact of Direct Conversation With Patients in the Compliance With the Split-dose Regimen Preparation for Colonoscopy Scheduled in the First Part of the Morning

Study Overview
=================
Brief Summary
-----------------
Split-dose cleansing regimens for colonoscopies, independently from the type of laxative used, are now recommended over full (one day)-dose regimens from all the major guidelines. It is wellknown that splitting the dose (half of the dose the night before and half the day of the colonoscopy) is safe and guarantees a better cleansing of the colon and thus a higher chance of identifying mucosal lesions. This is crucial both in terms of achieving a high-quality colonoscopy and in terms of time and money saved. Still, there are some issues about compliance and tolerability with split-dose regimens. Two recent prospective works have shown that only a small number of patients (33%) chooses the split-dose regimen when the colonoscopy is scheduled before 10 a.m. and when patients are forced to used the split-dose, 1/7 did not comply with it, especially if the procedure is before 10 a.m. The most common concerns are about early wake-up, travel interruption and fear of incontinence. Both these papers state that strategies to reduce this noncompliance are needed. The investigators aim to prove whether an active action (an oral explanation before the colonoscopy about why split-dose regimens are better) may improve patients' compliance in endoscopies scheduled in the early morning (from 8 to 10 a.m).

Conditions
-----------------
Colonoscopy Preparation Acceptance

Intervention / Treatment
-----------------
* Other: written + oral explanation
* Other: written explanation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: every patient who needs a colonoscopy Exclusion Criteria: incapacity in reading and/or in oral comprehension contraindications in drinking the preparation
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: written + oral explanation<br>patients will undergo both written and oral explanation for preparation with split dose | Other: written + oral explanation<br> <br> |
| Experimental: written explanation<br>patients will receive only a written explanation for preparation with split dose | Other: written explanation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients compliance in taking split-dose preparation in the early morning colonoscopies |  | 4 months |
Measurement of vanilloïd Compounds in Urin of Autistic vs Control Patients, as Potential Biomarkers

Study Overview
=================
Brief Summary
-----------------
In a former study, four vanilloid compounds were observed increased in the urin of autistic patients. The present study is aimed at performing a ambispective study to confirm or not these preliminary results. 70 urins from autistic children (already collected) will be compared to 70 urins of non autistic children (collected without intervention, remaining sample from the standard care), in terms of measurements of four vanilloid compounds using a GCMS apparatus.

Official Title
-----------------
Diagnostic of Autism by Measurement of vanilloïd Compounds in Urin

Conditions
-----------------
Autism Spectrum Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : For cases : Male children aged 2 years to less than 15 years inclusive years at time of sample collection Children with a diagnosis of autism (ICD-10 F84.0) after assessment by a child psychiatrist. For healthy chlidren: Children aged 2 years to less than 15 years old performing an ECBU at the CHRU of Nancy as part of their care. Patient whose ECBU is negative with respect to cytobacteriology (absence of urinary infection). Child can be matched to a CAS Exclusion criteria For cases: Children in whom one of the following pathologies is found during the anamnesis or in the clinical record : (i) renal insufficiency; (ii) urinary tract infection at the time of sampling and/or metabolic disease Children on antibiotic treatment at the time of collection For healthy chlidren : children whose urine culture come from one of the following departments: Pediatric Nephrology (potential risk of renal failure) or Pediatric Neurology (potential risk of neurological disorder). with a diagnosis of autism with a metabolic disease children undergoing antibiotic treatment at the time of collectio

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurements of vanilloid compound in urins | The primary end point is to determine if isolated or combinations of vanilloid compound measured in urin, may discriminate autistic vs non autistic childen | through study completion, an average of 18 months |
Recording Methods of Muscle Activity Onset.

Study Overview
=================
Brief Summary
-----------------
Delayed anticipatory muscle activity response in deep low back and abdominal muscles has been observed in patients with low back pain, indicative of a pathological condition. Muscle activity onset is traditionally recorded by intramuscular electromyography, but there is a need for a less cumbersome recording method in large clinical studies. The purpose of this experimental study is to explore whether high-frame rate m-mode ultrasound and tissue velocity imaging could measure anticipatory muscle responses (onset) in the abdominal muscles reliably and comparably accurate to intramuscular EMG.

Official Title
-----------------
Muscle Activity Onset in the Transversus Abdominis - Simultaneous Recordings by Intramuscular Electromyography and High Frame Rate Ultrasound Imaging.

Conditions
-----------------
Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy 30-65 yrs Exclusion Criteria: recent low back pain low back, neck or shoulder pain inflicting work absence or bed rest cardiac, rheumatic or other serious illness pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Low back pain, Neuromuscular control, Anticipatory motor control, Musculoskeletal Physiologic Processes, Muscle, Skeletal, Ultrasonography, Electromyography
Relation Between Ethanol Sclerotherapy for Endometrioma Systemic Immune Milieu

Study Overview
=================
Brief Summary
-----------------
Design: Prospective interventional study. 69 women with OE were evaluated clinically and by transvaginal ultrasonography (TUV). AEST procedure was performed and the collected aspirate and pre-procedural blood samples were collected for estimation of cytokines' levels. At 6-m post-procedure, clinical evaluation and TUV were repeated and serum cytokines' levels were re-estimated.

Official Title
-----------------
Endometrioma Cystic Fluid Aspiration and Retained Ethanol Sclerotherapy Might Improve the Systemic Immune Milieu

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Drug: Ethanol Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with OE of a mean diameter of >3 cm Exclusion Criteria: Women with recurrent OE a cyst that was suspicious of being malignant diabetes mellitus polycystic ovary syndrome body mass index (BMI) of >30 kg/m2 previous surgical interference that resulted in pelvic adhesions

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ovarian Endometrioma<br>Ovarian endometrioma (OE) is in women of reproductive age | Drug: Ethanol Injection<br>* The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of AEST procedures on patients' cytokines levels. | The effect of AEST on patients serum levels of tumor necrosis factor-α, interleukin-8 and interleukin-10 | 6 months |
fMRI Investigation of Depression in Patients With Epilepsy

Study Overview
=================
Brief Summary
-----------------
Depression is very common in epilepsy. Depression is the strongest predictor of poor quality of life in patients with epilepsy. The biological basis for depression in epilepsy remains poorly understood. This study uses functional MRI (fMRI) to examine brain response to emotional and non-emotional stimuli in healthy control subjects and in patients with epilepsy who are either depressed or not depressed. Results from this study will contribute to a better understanding of depression in epilepsy, which may eventually inform development of better treatment modalities..

Official Title
-----------------
fMRI Investigation of Depression in Patients With Epilepsy

Conditions
-----------------
Epilepsy, Depression

Participation Criteria
=================

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
epilepsy, depression, fMRI, emotion
Use of Antiseptic Solution for Vaginal Wash Before Cesarean Section

Study Overview
=================
Brief Summary
-----------------
To evaluate the rate of infections after cesarean sections in patients with premature rupture of membranes after vaginal wash either with an antiseptic solution (clorhexidine solution) vs. saline solution (placebo).

Official Title
-----------------
Use fo Antiseptic Solution for Vaginal Wash Before Cesarean Section in Patients With Premature Rupture of Membranes. A Randomized, Double Blind, Controlled Trial.

Conditions
-----------------
Operation Wound; Infection, Endometritis

Intervention / Treatment
-----------------
* Drug: Clorhexidine
* Drug: Saline solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with gestation between 34 and 41 6/7 weeks. Premature rupture of membranes (> 6 hours). Use of prophylactic antibiotic 1 hour previous to cesarean section. Exclusion Criteria: Any source of infection diagnosed previous to surgery. Fever of unknown origin previous to surgery.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Clorhexidine<br>Vaginal wash with clorhexidine solution | Drug: Clorhexidine<br>* Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.<br>|
| Placebo Comparator: Saline solution<br>Vaginal wash with saline solution | Drug: Saline solution<br>* Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cases of endometritis after cesarean section | Endometritis | 15 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of cases of cesarean site infection | Operative site infection | 15 days | 
| Number of cases of fever (38°C or above) in the puerperium | Puerperal fever | 15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cesarean, Operative site infection, Vaginal wash, Clorhexidine, Endometritis